141 related articles for article (PubMed ID: 34273660)
21. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.
Rabot M; El Costa H; Polgar B; Marie-Cardine A; Aguerre-Girr M; Barakonyi A; Valitutti S; Bensussan A; Le Bouteiller P
Int Immunol; 2007 Apr; 19(4):401-9. PubMed ID: 17307798
[TBL] [Abstract][Full Text] [Related]
22. HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.
Liu W; Chou TF; Garrett-Thomson SC; Seo GY; Fedorov E; Ramagopal UA; Bonanno JB; Wang Q; Kim K; Garforth SJ; Kakugawa K; Cheroutre H; Kronenberg M; Almo SC
J Exp Med; 2021 Dec; 218(12):. PubMed ID: 34709351
[TBL] [Abstract][Full Text] [Related]
23. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.
Rey J; Giustiniani J; Mallet F; Schiavon V; Boumsell L; Bensussan A; Olive D; Costello RT
Eur J Immunol; 2006 Sep; 36(9):2359-66. PubMed ID: 16917959
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
25. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
26. [CD160 binding to HVEM triggers an inhibitory signal to the activated T cell].
Bensussan A
Med Sci (Paris); 2008 Apr; 24(4):361-2. PubMed ID: 18405629
[No Abstract] [Full Text] [Related]
27. CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells.
Zhang L; Zhang A; Xu J; Qiu C; Zhu L; Qiu C; Fu W; Wang Y; Ye L; Fu YX; Zhao C; Zhang X; Xu J
Front Immunol; 2020; 11():2188. PubMed ID: 33072082
[TBL] [Abstract][Full Text] [Related]
28. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
29. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
[TBL] [Abstract][Full Text] [Related]
30. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14).
Ware CF; Sedý JR
Curr Opin Immunol; 2011 Oct; 23(5):627-31. PubMed ID: 21920726
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.
Abecassis S; Giustiniani J; Meyer N; Schiavon V; Ortonne N; Campillo JA; Bagot M; Bensussan A
J Invest Dermatol; 2007 May; 127(5):1161-6. PubMed ID: 17218942
[TBL] [Abstract][Full Text] [Related]
32. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
33. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
Barakonyi A; Rabot M; Marie-Cardine A; Aguerre-Girr M; Polgar B; Schiavon V; Bensussan A; Le Bouteiller P
J Immunol; 2004 Nov; 173(9):5349-54. PubMed ID: 15494480
[TBL] [Abstract][Full Text] [Related]
34. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
Giustiniani J; Marie-Cardine A; Bensussan A
J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
[TBL] [Abstract][Full Text] [Related]
35. Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Scheffges C; Devy J; Giustiniani J; Francois S; Cartier L; Merrouche Y; Foussat A; Potteaux S; Bensussan A; Marie-Cardine A
Breast Cancer Res; 2024 Feb; 26(1):28. PubMed ID: 38360636
[TBL] [Abstract][Full Text] [Related]
36. CD160 receptor in CLL: Current state and future avenues.
Oumeslakht L; Aziz AI; Bensussan A; Ben Mkaddem S
Front Immunol; 2022; 13():1028013. PubMed ID: 36420268
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
Giustiniani J; Bensussan A; Marie-Cardine A
J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
[TBL] [Abstract][Full Text] [Related]
38. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
[TBL] [Abstract][Full Text] [Related]
39. CD160 serves as a negative regulator of NKT cells in acute hepatic injury.
Kim TJ; Park G; Kim J; Lim SA; Kim J; Im K; Shin MH; Fu YX; Del Rio ML; Rodriguez-Barbosa JI; Yee C; Suh KS; Kim SJ; Ha SJ; Lee KM
Nat Commun; 2019 Jul; 10(1):3258. PubMed ID: 31332204
[TBL] [Abstract][Full Text] [Related]
40. CD160 Stimulates CD8
Tan CL; Peluso MJ; Drijvers JM; Mera CM; Grande SM; Brown KE; Godec J; Freeman GJ; Sharpe AH
Immunohorizons; 2018 Aug; 2(7):238-250. PubMed ID: 31022694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
